The S&P 500 Index stocks saw their aggregate trailing 12-month revenue per share increase at a compound average growth rate (CAGR) of 2% per annum over the past five years. The share price of the index has increased 105% over the past five years through Feb. 4.
Thus, investors may be interested in the following U.S.-listed equities, as they represent stocks that have outperformed the S&P 500 index in terms of superior revenue per share growth rates in recent years.
ICICI Bank Ltd
The first company that qualifies is ICICI Bank Ltd (IBN, Financial).
Based in Mumbai, India, ICICI Bank Ltd is a regional bank providing various banking products and other financial services to consumers, households and businesses in India and internationally.
The company saw its revenue per share increase by 8.5% on average every year over the past five years, as illustrated below.
The share price has gained almost 224% over the past five years to close at $17.35 on Thursday for a market capitalization of $59 billion and a 52-week range of $6.86 to $17.46.
Wall Street sell-side analysts recommend a median rating of buy for this stock and have produced an average target price of $17.88 per share for the stock, mirroring a 3% upside.
GuruFocus assigned the company a financial strength rating of 3 out of 10 and a profitability rating of 6 out of 10.
Texas Pacific Land Corp
The second company that qualifies is Texas Pacific Land Corp (TPL, Financial).
Based in Dallas, Texas, the company engages in the management of various land and related mineral resources in West Texas. The company is also a provider of water sourcing, disposal and treatment solutions as well as infrastructure development and well testing services.
The company saw its revenue per share increase by 59.5% on average every year over the past five years, as shown in the below chart.
The share price increased more than 7.5 times over the past five years to trade at $961.49 on Thursday's close. The stock has a market capitalization of $7.46 billion and a 52-week range of $295.05 to $973.99.
Wall Street sell-side analysts recommend an overweight median recommendation rating for this stock and have established an average target price of about $1,065.50 per share, reflecting a 10.8% growth.
GuruFocus assigned the company a financial strength rating of 7 out of 10 and a profitability rating of 10 out of 10.
NeoGenomics Inc
The third company that qualifies is NeoGenomics Inc (NEO, Financial).
Based in Fort Myers, Florida, NeoGenomics is a cancer diagnostics and research company operating a network of laboratories in the U.S., Switzerland and Singapore.
The company saw its revenue per share increase by 20.4% on average every year over the past five years.
The stock price has increased more than 8.5 times over the past five years to close at $53.60 per share on Thursday for a market capitalization of $6.17 billion and a 52-week range of $20.47 to $57.91.
Wall Street sell-side analysts recommend a median rating of buy for this stock and have generated an average target price of $57 per share, which represents a 6.34% increase from Thursday's closing price.
GuruFocus assigned the company a score of 5 out of 10 for both financial strength and profitability.
Disclosure: I have no positions in any securities mentioned in this article.
Read more here:
- A Trio of Low Price-Book Ratio Stock Picks
- A Trio of High Earnings Return Stocks
- 3 Stocks With Low Forward Price-Earnings Ratios
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
